Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The licensing of rights from Yale for the use of simufilam as a treatment for seizures related to rare neurodevelopmental disorders represents a noteworthy expansion of its therapeutic focus.
Cyborg Score Rationale
The U.S. Department of Justice had ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam. While the company has $106.1 million in cash reserves and is advancing TSC trials, the Phase 3 Alzheimer's program failed to meet primary endpoints, creating significant execution risk.
Top Insights
Phase 3 results for Simufilam in Alzheimer's Disease did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints, but confirmed simufilam's favorable safety profile.
Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy with recent appointment of experienced neuroscience leaders to guide clinical development strategy.
DOJ investigation closure eliminates significant legal overhang from research misconduct allegations.
Cash reserves of $149.0 million as of September 30, 2024 coupled with strategic reduction in operational expenses suggest Cassava is well-funded for continued operations through 2026.
Named Competitors
Anavex Life Sciences — Alzheimer's disease and neurodegeneration therapeutics
Annovis Bio — Neurodegenerative disease treatment development
Ocugen — CNS and rare disease drug development
Recent Developments
(Feb 2026) DOJ investigation into research misconduct closed
(Jan 2026) Publication of peer-reviewed Phase 3 Alzheimer's results showing failed primary endpoints but favorable safety
(Dec 2025) Settlement agreement for securities class action litigation
(Aug 2025) Appointment of Dr. Joseph Hulihan as Chief Medical Officer
Open the full interactive Cassava Sciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.